natgillin/translations-raw huggingface dataset:
The European Medicines Agency concluded that, in accordance with EU requirements, Pemetrexed Krka has been shown to be comparable to Alimta.
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Pemetreksed Krka primerljivo z zdravilom Alimta.
Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Alimta, and do not need to be repeated for Pemetrexed Krka.
Študije o koristih in tveganjih učinkovine pri odobrenih načinih uporabe so že bile izvedene z referenčnim zdravilom Alimta, zato jih ni treba ponoviti za zdravilo Pemetreksed Krka.
Because Pemetrexed Krka is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Pemetreksed Krka generično zdravilo in je bioekvivalentno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
This slows down the division of cancer cells, while normal cells are only slightly affected.
To upočasni množenje rakavih celic, medtem ko je vpliv na normalne celice zelo majhen.
What are the benefits and risks of Pemetrexed Krka?
Kakšne so koristi in tveganja zdravila Pemetreksed Krka?
Pemetrexed is converted into its active form more readily in cancer cells than in normal cells, leading to higher levels of the active form of the medicine and a longer duration of action in cancer cells.
Pemetreksed se v aktivno obliko lažje pretvori v rakavih celicah kot v normalnih celicah, kar privede do večje koncentracije aktivne oblike zdravila in njegovega daljšega učinkovanja v rakavih celicah.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pemetrexed Krka have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Pemetreksed Krka upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
As a result, the active form of pemetrexed slows down the formation of DNA and RNA and prevents the cells from dividing.
Aktivna oblika pemetrekseda nato upočasni tvorjenje DNK in RNK ter preprečuje, da bi se celice delile.
Pemetrexed Krka is a cancer medicine used to treat two types of lung cancer:
Zdravilo Pemetreksed Krka je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje dveh vrst pljučnega raka:
For more information about using Pemetrexed Krka, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Pemetreksed Krka glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
An overview of Pemetrexed Krka and why it is authorised in the EU
Pregled zdravila Pemetreksed Krka in zakaj je odobreno v EU
Pemetrexed Krka (pemetrexed)
Pemetreksed Krka (pemetreksed)
What is Pemetrexed Krka and what is it used for?
Kaj je zdravilo Pemetreksed Krka in za kaj se uporablja?
This means that Pemetrexed Krka contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Alimta.
To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje Alimta.
In the body, pemetrexed is converted into an active form that blocks the activity of the enzymes involved in producing nucleotides (the building blocks of DNA and RNA, the genetic material of cells).
Pemetreksed se v telesu pretvori v aktivno obliko, ki zavira delovanje encimov, ki sodelujejo pri tvorbi „nukleotidov“ (gradnikov DNK in RNK, genskega materiala celic).
Side effects reported with Pemetrexed Krka are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Pemetreksed Krka, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
There was no need for ‘bioequivalence' studies to investigate whether Pemetrexed Krka is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood.
Izvedba študije „bioekvivalence“, s katero bi raziskali, ali se zdravilo Pemetreksed Krka absorbira podobno kot referenčno zdravilo in tako doseže enako raven učinkovine v krvi, ni bila potrebna.
To reduce side effects, patients should take a corticosteroid (a type of medicine that reduces inflammation) and folic acid (a type of vitamin), and receive injections of vitamin B12 during treatment with Pemetrexed Krka.
Da bi zmanjšali neželene učinke, morajo bolniki med zdravljenjem z zdravilom Pemetreksed Krka jemati kortikosteroid (vrsto zdravila, ki ublaži vnetje) in folno kislino (vrsto vitamina) ter prejemati injekcije vitamina B12.
As for all medicines, data on the use of Pemetrexed Krka are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Pemetreksed Krka stalno spremljajo.
The active substance in Pemetrexed Krka, pemetrexed, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells), which belongs to the group ‘antimetabolites'.
Učinkovina v zdravilu Pemetreksed Krka, pemetreksed, je citotoksik (zdravilo, ki uničuje celice, ki se delijo, kot na primer rakave celice) iz skupine „antimetabolitov“.
This is because Pemetrexed Krka is given by infusion into a vein, so the active substance is delivered straight into the bloodstream.
Zdravilo Pemetreksed Krka se namreč daje z infundiranjem v veno, tako da učinkovina vstopa neposredno v krvni obtok.
When Pemetrexed Krka is given with cisplatin, an antiemetic medicine (to prevent vomiting) and fluids (to prevent dehydration) should also be given before or after the cisplatin dose.
Kadar se zdravilo Pemetreksed Krka daje v kombinaciji s cisplatinom, je treba pred odmerkom cisplatina ali po njem bolniku dati tudi „antiemetično“ zdravilo (za preprečevanje bruhanja) in tekočino (za preprečevanje dehidracije).
Therefore, the Agency's view was that, as for Alimta, the benefit of Pemetrexed Krka outweighs the identified risk and it can be authorised for use in the EU.
Zato je agencija menila, da koristi zdravila Pemetreksed Krka, enako kot pri zdravilu Alimta, odtehtajo znana tveganja in se zdravilo lahko odobri v EU.
Treatment should be delayed or stopped, or the dose reduced, in patients whose blood cell counts are low or who have certain other side effects.
Pri bolnikih z nizkim številom krvnih celic ali določenimi drugimi neželenimi učinki je treba zdravljenje odložiti ali prekiniti oziroma zmanjšati odmerek.
Other information about Pemetrexed Krka
Druge informacije o zdravilu Pemetreksed Krka
Pemetrexed Krka is available as a powder that is made up into a solution for infusion (drip) into a vein.
Zdravilo Pemetreksed Krka je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
How has Pemetrexed Krka been studied?
Kako je bilo zdravilo Pemetreksed Krka raziskano?
Pemetrexed Krka contains the active substance pemetrexed.
Zdravilo Pemetreksed Krka vsebuje učinkovino pemetreksed.
How does Pemetrexed Krka work?
Kako zdravilo Pemetreksed Krka deluje?
How is Permetrexed Krka used?
Kako se zdravilo Pemetreksed Krka uporablja?
1 year.
1 leto.
Risk Management plan (RMP)
Načrt za obvladovanje tveganja (RMP)
• if you have a severe infection with a high temperature (over 38°C).
• če imate hudo okužbo z visoko telesno temperaturo (višjo od 38 °C).
In such cases, the Western Blot method is negative.
V takšnih primerih je bil rezultat na osnovi metode Western blot negativen.
(see section 6.
(glejte poglavje 6.
Loc. Bellaria - 53018 Rosia - Sovicille (SI) Italy
Loc. Bellaria - 53018 Rosia - Sovicille (SI) Italija
The CHMP agrees with the scientific conclusions made by the PRAC.
CHMP se strinja z znanstvenimi zaključki odbora PRAC.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 12 August 2010
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET 12. avgust 2010
The use of a second dose should take into consideration the information provided in sections 4.4, 4.8 and 5.1.
Pri uporabi drugega odmerka je treba upoštevati informacije, navedene v poglavjih 4.4, 4.8 in 5.1.
The immune response to the seasonal antigens was satisfactory.
Imunski odziv na sezonske antigene je bil zadovoljiv.
Tell your doctor if you are pregnant, think you may be pregnant, plan to become pregnant.
Obvestite zdravnika, če ste noseči, mislite, da ste noseči ali načrtujete nosečnost.
Packs of 1 and 10.
Pakiranja po 1 in 10.
No data are available in children aged less than 6 months (see sections 4.8 and 5.1).
Za otroke, mlajše od 6 mesecev, ni podatkov (glejte poglavji 4.8 in 5.1).
In the first few weeks after vaccination with Focetria the results of these tests may not be correct.
V prvih tednih po cepljenju s cepivom Focetria so lahko rezultati takšnih testov napačni.
Warning: Do not inject intravascularly.
Opozorilo: ne injicirajte intravaskularno.
Children aged less than 6 months of age: Vaccination is currently not recommended in this age group.
Otroci, mlajši od 6 mesecev: V tej starostni skupini cepljenje trenutno ni priporočeno.
There were fewer reactions after the second vaccination compared with the first.
Po drugem cepljenju je bilo manj reakcij kot po prvem.
The majority of febrile convulsions occurred in paediatric subjects.
Večina febrilnih konvulzij se je pojavila pri pediatričnih bolnikih.
Tell your doctor if you have any known allergies.
Obvestite zdravnika, če imate kakršno koli alergijo.
The vaccine may be used during breast-feeding.
Cepivo se lahko uporablja med dojenjem.
Systemic
Sistemski
The vaccine contains an ‘adjuvant' (MF59C.1) to stimulate a better response.
Cepivo vsebuje "adjuvans" (MF59C.1) za spodbujanje boljšega odziva.
Instructions for administration of the vaccine:
Navodila za uporabo cepiva:
Data are available that suggest that multidose vials could be used up to a maximum of 72 hours after first withdrawal, although such pro-longed storage periods should not be the preferred option.
Na voljo so podatki, ki kažejo, da je treba večdomerno vialo porabiti v največ 72 urah po odvzemu prvega odmerka, vendar tako dolgo shranjevanje ni najbolj priporočljiva možnost.
Influenza vaccine, ATC Code: J07BB02
Cepivo proti gripi, oznaka ATC: J07BB02
This is a multidose container.
To je vsebnik za več odmerkov.
In any of these cases, TELL YOUR DOCTOR OR NURSE, as vaccination may not be recommended, or may need to be delayed.
V katerem koli od teh primerov POVEJTE ZDRAVNIKU ALI MEDICINSKI SESTRI, ker cepljenje morda ni priporočeno ali pa ga je treba opraviti pozneje.
Some of the effects mentioned under section 4.8 “Undesirable Effects” may affect the ability to drive or use machines.
Nekateri učinki, navedeni v poglavju 4.8 „Neželeni učinki“ lahko vplivajo na sposobnost vožnje in upravljanja s stroji.
Safety data are available in pregnant women exposed to Focetria in particular during second and third trimesters.
Na voljo so podatki o varnosti pri nosečnicah, izpostavljenih cepivu Focetria, še zlasti v drugem in tretjem trimesečju.
Doctors are aware of this possibility and have emergency treatment available for use in such cases.
Zdravnik se te možnosti zavedajo in imajo možnost urgentnega zdravljenje za take primere.
Multidose vial:
Večodmerna viala:
A minor infection such as a cold should not be a problem, but your doctor or nurse should advise whether you could still be vaccinated with Focetria,
Blažja okužba, kot je prehlad, ne predstavlja težave, vendar vam bosta zdravnik ali medicinska sestra morda svetovala, ali se lahko še vedno cepite s cepivom Focetria.
A clinical study was conducted with the same vaccine in children.
Pri otrocih so opravili klinično preskušanje z enakim cepivom.
21 days after 2nd dose (day 43)
21 dni po 2. odmerku (43. dan)
The dose recommendations take into account the safety and immunogenicity data from clinical studies in healthy subjects.
Priporočila za odmerjanje upoštevajo dostopne podatke o varnosti in imunogenosti iz kliničnih študij pri zdravih preiskovancih.
The PSUR cycle for the medicinal product should follow a half-yearly cycle until otherwise agreed by the CHMP
Cikel PSUR za zdravilo mora slediti polletnemu ciklu dokler CHMP ne odloči drugače.
Vaccination is not currently recommended in this age group.
Za to starostno skupino cepljenje trenutno ni priporočeno.
None of the ingredient in the vaccine can cause flu.
Sestavine cepiva ne morejo povzročiti gripe.
• The minimal data elements to be transmitted in individual case safety reports in order to facilitate the evaluation and the identification of the vaccine administered to each subject, including the invented name, the vaccine manufacturer and the batch number.
• Minimalne podatkovne elemente, ki jih je treba sporočiti v vsakem poročilu, da se olajša vrednotenje in identifikacija uporabljenega cepiva pri posamezni osebi, vključno z imenom cepiva, izdelovalcem ter številko serije.
For the adjuvant, see section 2.
Za adjuvans glejte poglavje 2.
A protective response may not be elicited in all vaccinees (see section 5.1).
Zaščitni imunski odziv morda ne bo dosežen pri vseh cepljenih osebah (glejte poglavje 5.1).
Although Focetria in multidose vials contains a preservative that inhibits microbial growth, minimisation of the risk of contamination of the multidose vial during withdrawal of each dose is the responsibility of the user.
Čeprav vsebuje cepivo Focetria v večodmerni viali konzervans, ki zavira rast mikrobov, je minimiranje tveganja onesnažitve večodmerne viale med odvzemom vsakega odmerka odgovornost uporabnika.
• Adverse events to be prioritised for reporting, i.e. fatal and life-threatening adverse reactions, unexpected severe adverse reactions, adverse events of special interest (AESI).
• Neželene učinke, ki imajo pri prijavljanju prednost, tj. smrtne in življenje ogrožajoče neželene učinke, nepričakovane hude neželene učinke, neželene dogodke posebnega pomena (AESI).
9.75 milligrams polysorbate 80
9,75 miligramov polisorbat 80
The multidose vial should preferably be used within 24 hours after first withdrawal.
Najbolje je, da večodmerno vialo porabite v 24 urah po odvzemu prvega odmerka.
The vaccine will be injected into a muscle (usually in the upper arm).
Cepivo vam bodo injicirali v mišico (ponavadi v nadlaket).
Pharmacotherapeutic group: Vaccines.
Farmakoterapevtska skupina: cepiva.
What you need to know before you receive FOCETRIA
Kaj morate vedeti, preden boste prejeli cepivo FOCETRIA
Packs of 10.
Pakiranja po 10.
• If a specific notification system has been put in place, how to report adverse reactions.
• Način poročanja, če je vzpostavljen poseben sistem poročanja o neželenih učinkih.
It is widely accepted that the adjuvant effect leading to increased immunogenicity is associated with a slightly higher frequency of local reactions (mostly mild pain) compared with conventional, nonadjuvanted influenza vaccines.
Na splošno velja, da je učinek adjuvansa, ki poveča imunogenost cepiva, povezan z nekoliko večjo pogostnostjo lokalnih reakcij (večinoma blagih bolečin) v primerjavi z običajnimi cepivi proti gripi brez adjuvansov.
• Official batch release In accordance with Article 114 Directive 2001/83/EC as amended, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.
V skladu s 114. členom Direktive 2001/83/ES z vsemi dopolnitvami in spremembami, serijo uradno sprosti državni laboratorij ali laboratorij, določen v ta namen.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness:
V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti.
You or your child will receive one dose of 0.5 ml vaccine.
Vi ali vaš otrok boste dobili en odmerek 0.5 ml cepiva.
* propagated in eggs ** expressed in microgram haemagglutinin.
* razmnožen v jajcih ** izraženo v mikrogramih hemaglutinina
Adjuvant MF59C.1 containing: squalene
Adjuvans MF59C.1 vsebuje: skvalen
Immunogenicity data obtained at three weeks after one dose of Focetria H1N1v suggest that a single dose may be sufficient.
Podatki o imunogenosti, dobljeni tri tedne po enem odmerku cepiva Focetria H1N1v kažejo, da en sam odmerek zadošča.
Focetria should be used in accordance with Official Guidance.
Cepivo Focetria je treba uporabljati v skladu z uradnimi priporočili.
In the clinical studies with the vaccine, most side effects were mild in nature and short term.
V kliničnih študijah s cepivom je bila večina neželenih učinkov blagih in kratkotrajnih.
Health care providers need to assess the benefits and potential risks of administering Focetria vaccine to pregnant women, taking into consideration official recommendations.
Zdravstveni delavci morajo oceniti koristi in morebitna tveganja dajanja cepiva Focetria nosečnicam in pri tem upoštevati uradna priporočila.
• The MAH shall agree with Member States on mechanisms allowing patients and health care professionals to have continuous access to updated information regarding Focetria.
• Imetnik dovoljenja za promet z zdravilom se bo dogovoril z državami članicami o mehanizmih, ki bodo bolnikom in zdravnikom omogočali stalen dostop do posodobljenih informacij o cepivu Focetria.
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.
Kot pri vseh cepivih, ki se injicirajo, morata biti ustrezno zdravljenje in zdravstveni nadzor vedno na voljo za primer redkih anafilaktičnih reakcij po uporabi cepiva.
These side effects usually disappear within 1-2 days without treatment.
Ti neželeni učinki navadno izginejo v 1 do 2 dneh brez zdravljenja.
• The MAH shall agree with Member States to measures facilitating the identification and traceability of the A/H1N1 vaccine administered to each patient, in order to minimise medication errors and aid patients and health care professionals to report adverse reactions.
• Imetnik dovoljenja za promet z zdravilom se bo dogovoril z državami članicami o ukrepih za lažjo identifikacijo in sledljivost cepiva proti virusu A/H1N1, ki se bo uporabilo pri posameznem bolniku, da bi se zmanjšale napake pri uporabi zdravila ter v pomoč bolnikom in zdravnikom pri poročanju o neželenih učinkih.
The physician should inform you about the possibility to experience convulsion, in particular if you have had previous history of epilepsy.
Zdravnik vas mora obvestiti o možnosti, da boste doživeli krče, zlasti, če imate (ali ste v preteklosti imeli) epilepsijo.
Tell your doctor or nurse if you are taking or have recently taken any other medicines, including medicines obtained without a prescriptionor have recently been given any other vaccine.
Obvestite svojega zdravnika ali medicinsko sestro, če jemljete ali ste pred kratkim jemali katero koli zdravilo, tudi če ste ga dobili brez recepta, ali če ste se pred kratkim cepili z drugim cepivom.
This vaccine in a multi-dose vial contains thiomersal as a preservative and it is possible that you may experience an allergic reaction.
To cepivo v večodmernem vsebniku vsebuje tiomersal kot konzervans in obstaja možnost, da se pri vas pojavi alergijska reakcija.
One dose of 0.5 ml at an elected date.
En odmerek 0,5 ml se uporabi na izbrani datum.
The side effects listed below have occurred in the days or weeks after vaccination with Focetria.
Spodaj navedeni neželeni učinki so se pojavili v dneh ali tednih po cepljenju s cepivom Focetria.
You should discuss with your doctor whether you should receive Focetria taking into consideration official recommendation based on post-marketing reported adverse events during second and third trimesters of pregnancy.
Posvetujte se s svojim zdravnikom, ali se lahko cepite s cepivom Focetria, pri čemer je treba upoštevati uradna priporočila na osnovi neželenih učinkov, o katerih so poročali v obdobju trženja zdravila, v drugem in tretjem trimesečju nosečnosti.
Detailed information on this product is available on the website of the European Medicines Agency (EMA): http://www.ema.europa.eu/.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/.
In the event that a second dose is to be administered it should be noted that there are no safety, immunogenicity or efficacy data to support interchangeability of Focetria with other H1N1v vaccines.
V kolikor se daje drugi odmerek cepiva, se je treba zavedati, da ni podatkov o varnosti, imunogenosti ali učinkovitosti, ki bi potrjevali zamenljivost cepiva Focetria z drugimi cepivi proti H1N1v.
The common reactions usually disappear within 1-2 days without treatment.
Pogosti neželeni učinki navadno izginejo v 1-2 dneh brez zdravljenja.
Safety data after the first and second dose in children and adolescents suggest a comparable safety profile with that reported for the H5N1 mock-up vaccine formulation.
Varnostni podatki po prvem in drugem odmerku za otroke in mladostnike kažejo varnostni profil, ki je primerljiv z varnostnim profilom modelnega cepiva H5N1.
The MAH shall perform the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the RMP presented in Module 1.8.2. of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the Committee for Medicinal Products for Human Use CHMP.
Imetnik dovoljenja za promet z zdravilom bo izvedel študije in dodatne farmakovigilančne aktivnosti, podrobno opisane v načrtu farmakovigilance, sprejetem v RMP, predloženem v modulu 1.8.2 vloge za pridobitev dovoljenja za promet in vseh nadaljnih posodobitvah RMP v soglasju z Odborom za zdravila za uporabo v humani medicini (CHMP).
Therefore, healthcare providers need to assess the benefits and potential risks of administering the vaccine in individuals with thrombocytopenia or any bleeding disorder that would contraindicate intramuscular injection unless the potential benefit outweighs the risk of bleedings.
Zato mora zdravnik oceniti koristi in možna tveganja uporabe cepiva pri osebah s trombocitopenijo ali kakršno koli motnjo strjevanja krvi, ki bi bila kontraindikacija za intramuskularno injiciranje, razen če možna korist odtehta tveganje krvavitve.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALCI BIOLOŠKE ZDRAVILNE UČINKOVINE IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
• Safety and immunogenicity data obtained after administration of a one or two doses of Focetria
• Podatki o varnosti in imunogenosti, dobljeni po uporabi enega ali dveh odmerkov cepiva
Children aged less than 6 months:
Otroci, mlajši od 6 mesecev:
These transitory false positive results may be due to IgM production in response to the vaccine.
Prehodno lažno pozitivni rezultati so lahko posledica nastajanja protiteles IgM kot odziv na cepivo.
Immunisation should be postponed in patients with severe febrile illness or acute infection.
Cepljenje pri bolnikih s hudo febrilno boleznijo ali akutno okužbo naj se preloži.
• Studies in adults and elderly:
• Študije z odraslimi in starostniki:
This medicinal product contains thiomersal (an organomercuric compound) as a preservative and therefore, it is possible that sensitisation reactions may occur (see section 4.4).
To zdravilo vsebuje tiomersal (živosrebrova organska spojina) kot konzervans, zato lahko pride do senzibilizacije (glejte poglavje 4.4).
Side effects from clinical studies in children
Neželeni učinki v kliničnih preskušanjih z otroki
This medicinal contains less than 1 mmol sodium (23 mg) and less than 1 mmol of potassium (39 mg) per 0.5 ml dose, i.e. essentially sodium- and potassium free.
To cepivo vsebuje manj kot 1 mmol natrija (23 mg) in manj kot 1 mmol kalija (39 mg) na odmerek 0,5 ml, kar pomeni, da je v bistvu brez natrija in kalija.
There is a further immune response to a second dose of 0.5 ml administered after an interval of three weeks.
Obstaja dodatni imunski odziv na drugi odmerek 0,5 ml, uporabljen po presledku 3 tednov.
Other medicines and Focetria
Druga zdravila in cepivo Focetria
- Via Fiorentina, 1 - Siena, Italy.
- Via Fiorentina, 1 - Siena, Italija.